VKTX 241129 49.00C (VKTX241129C49000) Stock Options, News & Quotes

US OptionsDetailed Quotes

VKTX241129C49000

Watchlist

5.00
-1.38-21.63%

15min DelayClose Nov 27 16:00 ET

5.00High5.00Low

Intraday

5D
Daily

News

Will weight loss drugs be included in the US medical insurance, becoming the strongest "roadblock" for the Trump team?
The "Dual Weight Loss Champions" led the significant rise.
Gelonghui FinanceNov 26 20:45 ET
BTIG Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $125
Moomoo NewsNov 26 17:31 ET · Ratings
Amgen Obesity Drug Falls Short of Efficacy Expectations in Trial, Mizuho Says; Shares Decline
MT NewswiresNov 26 16:00 ET
H.C. Wainwright Maintains Viking Therapeutics(VKTX.US) With Buy Rating, Maintains Target Price $102
Moomoo NewsNov 26 12:32 ET · Ratings
Express News | HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $102 Price Target
BenzingaNov 26 11:47 ET
Viking Therapeutics' VK2735: A Leading Contender in Obesity Treatment With Strong Performance and Safety Profile
TipRanksNov 26 11:45 ET

Comments

Shaaaw

13 hours ago

Today, $Amgen (AMGN.US)$ announced the P2 trial results for MariTide, which only include the safety profile for the 420 mg dose escalation cohorts (cherry-picking at it's finest again).
I suspect they chose not to present the full safety profile, given that the weight loss results for the 120 mg and 280 mg QM cohorts, in obese non-diabetics (without dose escalations), at week 16 in P2 are consistent with the P1 results (see slide 1). So, it is likely that the 120 mg and 280 mg QM (without dose...